AbbVie announced that the independent directors of the board have selected Roxanne Austin as lead independent director, effective July 1. Austin succeeds Glenn Tilton, who has served as lead independent director since 2013. Tilton will continue to serve on the AbbVie Board as an independent director.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie: FDA approves SKYRIZI for ulcerative colitis
- AbbVie price target raised to $190 from $185 at Piper Sandler
- AbbVie Recommends Shareholders Reject Tutanota’s “Mini-Tender” Offer
- AbbVie recommends shareholders reject Tutanota’s ‘mini-tender’ offer
- MRK, ABBV, LI: 3 Low-Beta Stocks with Upside Potential